药物之间的相互作用1329045个记录(本栏目收费,不能展示细节,电话13136136841)
药物之间的相互作用
Podofilox
Pipemidic acid
The risk or severity of QTc prolongation can be increased when Pipemidic acid is combined with Pazopanib.
Podofilox
Rufloxacin
The risk or severity of QTc prolongation can be increased when Rufloxacin is combined with Pazopanib.
Podofilox
Lidoflazine
The risk or severity of QTc prolongation can be increased when Lidoflazine is combined with Pazopanib.
Podofilox
Piromidic acid
The risk or severity of QTc prolongation can be increased when Piromidic acid is combined with Pazopanib.
Podofilox
Acetyldigoxin
The risk or severity of QTc prolongation can be increased when Acetyldigoxin is combined with Pazopanib.
Podofilox
Lorajmine
The risk or severity of QTc prolongation can be increased when Lorajmine is combined with Pazopanib.
Podofilox
Oxolinic acid
The risk or severity of QTc prolongation can be increased when Oxolinic acid is combined with Pazopanib.
Podofilox
Prajmaline
The risk or severity of QTc prolongation can be increased when Prajmaline is combined with Pazopanib.
Podofilox
Bencyclane
The risk or severity of QTc prolongation can be increased when Bencyclane is combined with Pazopanib.
Podofilox
Cibenzoline
The risk or severity of QTc prolongation can be increased when Cibenzoline is combined with Pazopanib.
Podofilox
Cicletanine
The risk or severity of QTc prolongation can be increased when Cicletanine is combined with Pazopanib.
Podofilox
Pilsicainide
The risk or severity of QTc prolongation can be increased when Pilsicainide is combined with Pazopanib.
Podofilox
Givinostat
The risk or severity of QTc prolongation can be increased when Givinostat is combined with Pazopanib.
Podofilox
Temefos
The risk or severity of QTc prolongation can be increased when Temefos is combined with Pazopanib.
Podofilox
Tetrahydropalmatine
The risk or severity of QTc prolongation can be increased when Tetrahydropalmatine is combined with Pazopanib.
Podofilox
Prulifloxacin
The risk or severity of QTc prolongation can be increased when Prulifloxacin is combined with Pazopanib.
Podofilox
CUDC-907
The risk or severity of QTc prolongation can be increased when CUDC-907 is combined with Pazopanib.
Podofilox
Anisodamine
The risk or severity of QTc prolongation can be increased when Anisodamine is combined with Pazopanib.
Podofilox
Talinolol
The risk or severity of QTc prolongation can be increased when Talinolol is combined with Pazopanib.
Podofilox
Rupatadine
The risk or severity of QTc prolongation can be increased when Rupatadine is combined with Pazopanib.